Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry

  • Carlos Fernández Carrillo
    Liver Unit,Hospital Universitario Puerta de Hierro‐Majadahonda,IDIPHIM, CIBERehd, Majadahonda,Madrid,Spain
  • Sabela Lens
    Liver Unit,Hospital Clínic de Barcelona, University of Barcelona,IDIBAPS, CIBERehd,Barcelona,Spain
  • Elba Llop
    Liver Unit,Hospital Universitario Puerta de Hierro‐Majadahonda,IDIPHIM, CIBERehd, Majadahonda,Madrid,Spain
  • Juan Manuel Pascasio
    Department of Gastroenterology,Hospital Universitario Virgen del Rocío,IBIS, CIBERehd,Sevilla,Spain
  • Javier Crespo
    Gastroenterology and Hepatology Unit, Hospital Universitario Marqués de Valdecilla, Santander, IDIVAL,Universidad de Cantabria,Santander,Spain
  • Juan Arenas
    Department of Gastroenterology,Hospital Universitario Donostia,San Sebastián,Spain
  • Inmaculada Fernández
    Department of Gastroenterology,Hospital Universitario 12 de Octubre,Madrid,Spain
  • Carme Baliellas
    Digestive Service, Hospital Universitario de Bellvitge,L'Hospitalet de Llobregat,Barcelona,Spain
  • José Antonio Carrión
    Liver Section, Gastroenterology Department,Hospital del Mar,IMIM,Barcelona,Spain
  • Manuel de la Mata
    Hepatology & Liver Transplant Unit,Hospital Universitario Reina Sofía,IMIBIC, CIBERehd,Córdoba,Spain
  • Maria Buti
    Liver Unit,Hospital Universitario Vall d'Hebrón,CIBERehd,Barcelona,Spain
  • Lluís Castells
    Liver Unit,Hospital Universitario Vall d'Hebrón,CIBERehd,Barcelona,Spain
  • Agustín Albillos
    Gastroenterology and Hepatology Department, Hospital Universitario Ramón y Cajal,University of Alcalá, IRYCIS, CIBERehd,Madrid,Spain
  • Manuel Romero
    Digestive Diseases Unit,Hospital Universitario Virgen de Valme,CIBERehd,Sevilla,Spain
  • Juan Turnes
    Department of Gastroenterology,Complejo Hospitalario Universitario de Pontevedra and IISGS,Pontevedra,Spain
  • Clara Pons
    Digestive Service,Hospital General Universitario de Castellón,Castellón de la Plana,Spain
  • José María Moreno‐Planas
    Department of Gastroenterology,Complejo Hospitalario Universitario de Albacete,Albacete,Spain
  • José Javier Moreno‐Palomares
    Internal Medicine,Hospital General de Segovia,Segovia,Spain
  • Conrado Fernández‐Rodriguez
    Department of Gastroenterology,Hospital Universitario Fundación Alcorcón,Alcorcón,Madrid,Spain
  • Javier García‐Samaniego
    Liver Unit,Hospital Universitario La Paz,CIBERehd, IdiPAZ,Madrid,Spain
  • Martín Prieto
    Servicio de Medicina Digestiva, Unidad de Hepatología,Hospital Universitari i Politècnic La Fe and CIBERehd,Valencia,Spain
  • Miguel Fernández Bermejo
    Digestive Service,Hospital San Pedro de Alcántara,Cáceres,Spain
  • Javier Salmerón
    Digestive Service,Hospital Universitario San Cecilio,CIBERehd,Granada,Spain
  • Ester Badia
    Digestive Service,Hospital Universitario de Burgos,Burgos,Spain
  • Magdalena Salcedo
    Liver Unit,Hospital General Universitario Gregorio Marañón,IiSGM,Madrid,Spain
  • José Ignacio Herrero
    Liver Unit,Clínica Universitaria de Navarra,IdiSNA, CIBERehd,Pamplona,Spain
  • Rafael Granados
    Internal Medicine Service,H. U. de Gran Canaria Dr. Negrín,Las Palmas de Gran Canaria,Spain
  • Michel Blé
    Servidigest Clinic of Barcelona,Spain
  • Zoe Mariño
    Liver Unit,Hospital Clínic de Barcelona, University of Barcelona,IDIBAPS, CIBERehd,Barcelona,Spain
  • José Luis Calleja
    Liver Unit, Hospital Universitario Puerta de Hierro‐Majadahonda,Universidad Autónoma de Madrid and CIBERehd,Madrid,Spain

抄録

<jats:p>Direct‐acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in patients from the Spanish Hepa‐C registry investigated the effectiveness and safety of interferon‐free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered). Patients transplanted during treatment or within 12 weeks of completing treatment were excluded. Among 843 patients with cirrhosis (Child‐Turcotte‐Pugh [CTP] class A, n = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12). Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP class B/C patients (94% versus 78%, and 4% versus 14%, respectively; both <jats:italic toggle="yes">P</jats:italic> < 0.001). Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class A patients (50% versus 12%, respectively; <jats:italic toggle="yes">P</jats:italic> < 0.001). Incident decompensation was the most common serious adverse event (7% overall). Death rate during the study period was 16/843 (2%), significantly higher among CTP class B/C versus CTP class A patients (6.4% versus 0.9%; <jats:italic toggle="yes">P</jats:italic> < 0.001). Baseline Model for End‐Stage Liver Disease (MELD) score alone (cut‐off 18) was the best predictor of survival. <jats:italic toggle="yes">Conclusion</jats:italic>: Patients with decompensated cirrhosis receiving DAAs present lower response rates and experience more SAEs. In this setting, a MELD score ≥18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (H<jats:sc>epatology</jats:sc> 2017;65:1810‐1822).</jats:p>

収録刊行物

  • Hepatology

    Hepatology 65 (6), 1810-1822, 2017-04-28

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ